- 8Sep, 2025
Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.
TAXIS Pharmaceuticals Publishes on FtzS Inhibitors in the Journal of Antibiotics
FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. In this paper, we present the screening and evaluation of a benzamide class that is functionalized at the alkoxy fragment targeting Gram-negative bacteria.
TAXIS Publishes on Efflux Pump Inhibitors in MDPI Journal Antibiotics
Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.
TAXIS Pharmaceuticals appears in August special issue on Antibiotic Alternatives in ACS Infectious Diseases
Efflux Pump Inhibitor (EPI) drug candidates appears in the August 13th special Antibiotic Alternatives issue of ACS Infectious Diseases. The paper titled “The CARB-X Portfolio of Nontraditional Antibacterial Products”
- 20Feb, 2025
On April 15, 2021, the World Health Organization (WHO) released their report titled “2020 Antibacterial Agents in Clinical and Preclinical Development” naming TAXIS Pharmaceuticals’ FtsZ inhibitor drug candidate TXA709 as one of only 2 (out of 26) antibacterials targeting WHO priority pathogens that meet all of the WHO innovation criteria (absence of known cross resistance, new class, new target; new mode of action).
